Literature DB >> 17868365

Vacuolization correlates with spin-spin relaxation time in motor brainstem nuclei and behavioural tests in the transgenic G93A-SOD1 mouse model of ALS.

Selina Bucher1, Kerstin E Braunstein, Heiko G Niessen, Thomas Kaulisch, Michael Neumaier, Tobias M Boeckers, Detlef Stiller, Albert C Ludolph.   

Abstract

In recent years, magnetic resonance imaging (MRI) has emerged as a preferred tool for the diagnosis of amyotrophic lateral sclerosis (ALS) in humans. A widely used animal model for human ALS is the G93A-superoxide dismutase 1 (G93A-SOD1) transgenic mouse model. However, the mechanisms for the selective degeneration of motor neurons in the brainstem and spinal cord are still uncertain. In our study, we applied MRI at 4.7 Tesla to non-invasively evaluate pathological alterations in the brainstem of this animal model and to follow the progression of the disease. Extending previous investigation, we used the relaxation parameter T(2) as a suitable measure for the progression of ALS, and evaluated the potential agreement with histological evaluation and behavioural data of open-field tests. In the brainstem of G93A-SOD1 mice, T(2) values were significantly increased in the motor nuclei Nc. V, Nc. VII and Nc. XII, as early as Day 80, i.e. before the average disease onset at about Day 90. Moreover, this increase is associated with a progressive development of vacuoles in the brainstem motor nuclei and a significantly decreased performance in behavioural tests. Overall, MRI is a very sensitive tool to obtain correlates for neuronal degeneration in vivo. Furthermore, MRI enables us to investigate a follow up at different time points of the disease. These advantages are especially useful for therapeutic studies with respect to survival rates of motor neurons using mouse models. Finally, our data suggest that MRI does not only resemble the findings of behavioural tests, but is potentially superior to behavioural studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17868365     DOI: 10.1111/j.1460-9568.2007.05831.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  7 in total

1.  Evidence-based drug treatment in amyotrophic lateral sclerosis and upcoming clinical trials.

Authors:  Albert C Ludolph; Sarah Jesse
Journal:  Ther Adv Neurol Disord       Date:  2009-09       Impact factor: 6.570

Review 2.  MRI in rodent models of brain disorders.

Authors:  Aleksandar Denic; Slobodan I Macura; Prasanna Mishra; Jeffrey D Gamez; Moses Rodriguez; Istvan Pirko
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

3.  An animal model of oral dysphagia in amyotrophic lateral sclerosis.

Authors:  Teresa E Lever; Ambre Gorsek; Kathleen T Cox; Kevin F O'Brien; Norman F Capra; Monica S Hough; Alexander K Murashov
Journal:  Dysphagia       Date:  2008-12-24       Impact factor: 3.438

4.  Imaging of brain TSPO expression in a mouse model of amyotrophic lateral sclerosis with (18)F-DPA-714 and micro-PET/CT.

Authors:  S Gargiulo; S Anzilotti; A R D Coda; M Gramanzini; A Greco; M Panico; A Vinciguerra; A Zannetti; C Vicidomini; F Dollé; G Pignataro; M Quarantelli; L Annunziato; A Brunetti; M Salvatore; S Pappatà
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-27       Impact factor: 9.236

5.  Comparative Magnetic Resonance Imaging and Histopathological Correlates in Two SOD1 Transgenic Mouse Models of Amyotrophic Lateral Sclerosis.

Authors:  Ilaria Caron; Edoardo Micotti; Alessandra Paladini; Giuseppe Merlino; Laura Plebani; Gianluigi Forloni; Michel Modo; Caterina Bendotti
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

6.  CNS-targeted glucocorticoid reduces pathology in mouse model of amyotrophic lateral sclerosis.

Authors:  Matthew C Evans; Pieter J Gaillard; Marco de Boer; Chantal Appeldoorn; Rick Dorland; Nicola R Sibson; Martin R Turner; Daniel C Anthony; Helen B Stolp
Journal:  Acta Neuropathol Commun       Date:  2014-06-13       Impact factor: 7.801

7.  T₂-weighted MRI detects presymptomatic pathology in the SOD1 mouse model of ALS.

Authors:  Matthew C Evans; Sébastien Serres; Alexandre A Khrapitchev; Helen B Stolp; Daniel C Anthony; Kevin Talbot; Martin R Turner; Nicola R Sibson
Journal:  J Cereb Blood Flow Metab       Date:  2014-02-05       Impact factor: 6.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.